Injectable Leqembi permits weekly maintenance dosing of the Eisai and Biogen Alzheimer’s disease drug that may be done at a patient’s home. Other recent notable regulatory news includes several rare disease drug approvals and narrower FDA nods for Covid-19 vaccines. The post Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug appeared first on MedCity News.| MedCity News
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
The U.S. FDA has approved monthly maintenance dosing for Leqembi, a treatment for early Alzheimer’s disease.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today